


**Supplementary figure 3: Kaplan Meier survival curves showing post-NivoPFS for gemcitabine, docetaxel and erlotinib**



Patients at risk (gem)	27	19	6	5	3	2	1
Patients at risk (doce)	25	17	9	5	3	3	2
Patients at risk (erlo)	18	7	2	1			